Goldman Sachs Downgrades Charles River Labs (CRL) to Sell, Adds to Conviction Sell List
More News related to CRL
- Barclays Downgrades Charles River Labs (CRL) to Equal Weight
- Morning Movers 11/04: MPAC, ABK, GNVC, RHB, IRE, PACR Higher; STEC, CLRT, VG, TRLG, ANSW Lower
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Charles River (CRL) Beats Q3 Views by 5c; Lowers FY09 EPS Guidance
- Charles River Announces Third-Quarter 2009 Results
More News related to Downgrades
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Natixis Bleichroeder Downgrades Tenaris S.A. (TS) to Reduce
- Bank of America Downgrades Seneca Foods (SENEB) from Buy
- RBC Downgrades Intrepid Potash (IPI) to Sector Perform
Goldman Sachs downgrades Charles River Laboratories (NYSE: CRL) from Neutral to Sell and also adds the stock to its Conviction Sell List.
Shares of Charles River Labs initially sold-off on the downgrade, gapping about 2.8% lower at the open. The stock has rebounded slightly and is now trading down just 0.6%.
Charles River Laboratories International, Inc., together with its subsidiaries, provides solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services worldwide.
Related Categories
DowngradesStocks Mentioned
-0.70Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
